



XII SEPNWG Meeting and IPNA Teaching Course

16–17 October 2026

Sofia

Hyatt regency Sofia

SCIENTIFIC PROGRAM

Day 0 (Thursday, 15 October 2026)

Time	Session	Topic	Speaker
19:00–20:00	Business meeting		ORGANIZING COMMITTEE

Day 1 (Friday, 16 October 2026)

Time	Session	Topic	Speaker/ Country	Chairperson/ Country
07:30–08:30	Registration			
08:30–08:40	Opening Remark			

First session SSNS and SRNS (part 1)

08:40–09:00	Oral 1	SSNS	FRANCESCO EMMA (Rome, Italy)	DIETER HAFFNER (Hannover, Germany) VELIBOR TASIĆ (Skopje, North Macedonia)
09:00–09:20	Oral 2	Volume assessment in nephrotic syndrome	GRETA MIHNEVA (Sofia, Bulgaria)	
09:20–09:40	Oral 3	The role of Rituximab in nephrotic syndrome	KJELL TULLUS (London, UK)	
09:40–10:00	Oral 4	Histological challenges of childhood nephrotic syndrome: one “new old story”	JULIAN ANANIEV (Stara Zagora, Bulgaria)	
10:00–10:10		Discussion		

10:10–10:40	Coffee Break			
-------------	---------------------	--	--	--

Second session SSNS and SRNS (part 2)

10:40–11:00	Oral 5	SRNS: Lessons from the IPNA guideline	DIETER HAFFNER (Hannover, Germany)	
-------------	--------	---------------------------------------	---	--

11:00–11:20	Oral 6	The genetics of SRNS – what’s next?	OLGA BELTCHEVA (Sofia, Bulgaria)	KJELL TULLUS (London, UK) DANKA POKRAJAC (Saraevo, BiH)
11:20–11:40	Oral 7	Role of immunosuppression or other treatment options in genetic podocytopathies	GEORGIA MALAKASIOTI (Athens, Greece)	
11:40–12:00	Oral 8	SRNS in Bulgarian children – one center experience	GALYA ZLATANOVA (Sofia, Bulgaria)	
12:00–12:10		Discussion		
12:10–13:30	Lunch Break			
13:30–14:00	Scientific symposium Supported by GENESIS PHARMA	Primary hyperoxaluria Type 1 (PH1) in children	CONSTANTINOS STEFANIDIS (Athens, Greece)	
Third session IgA nephropathy				
14:00–14:20	Oral 9	IPNA clinical practice recommendations on IgA nephropathy	DIETER HAFFNER (Hannover, Germany)	FRANCESCO EMMA (Rome, Italy) PATRICIA COSTA-REIS (Lisbon, Portugal)
14:20–14:40	Oral 10	Recent advances in pediatric IgA nephropathy	DANKO MILOSEVIC (Zagreb, Croatia)	
14:40–15:00	Oral 11	Association of glutathione transferase gene polymorphisms with IgA vasculitis disease severity	DANIEL TURUDIC (Zagreb, Croatia)	
15:00–15:10		Discussion		
15:10–15:40	Coffee Break			
15:40–16:00	Scientific symposium Supported by AstraZeneca	aHUS	DIMITAR ROUSSINOV (Sofia, Bulgaria)	
Fourth session Various				
16:00–16:20	Oral 12	Acute poststreptococcal glomerulonephritis: from dogma to evidence	VELIBOR TASIĆ (Skopje, North Macedonia)	

16:20–16:40	Oral 13	Atypical poststreptococcal glomerulonephritis	DUSAN PARIPOVIC (Belgrade, Serbia)	DANKO MILOSEVIC (Zagreb, Croatia) VARVARA ASKITI (Athens, Greece)
16:40–17:00	Oral 14	Membranous nephropathy in children: Epidemiology, treatment and outcome	JULIEN HOGAN (Paris, France)	
17:00–17:20	Oral 15	Membranous nephropathy: diverse pathogenic pathways, similar morphological lesions	FRANCESCA DIOMEDI- CAMASSEI (Rome, Italy)	
17:20–17:40	Oral 16	Challenges and advances in Crescentic glomerulonephritis	VALBONA NUSHI STAVILECI (Pristina, Kosovo)	
17:40–18:00	Oral 17	Goodpasture syndrome	MARIA GAYDAROVA (Sofia, Bulgaria)	
18:00–18:30		Discussion		

Day 2 (Saturday, 17 October 2026)				
Time	Session	Topic	Speaker/ Country	Chairperson/ Country
Fifth session C3 GN, IC-MPGN				
08:30–08:50	Oral 18	Renal tubular acidosis	FRANCESCO EMMA (Rome, Italy)	
08:50–09:00	Scientific symposium Supported by SWIXX BIOPHARMA	Fabry disease in pediatric patients	MARIAN STEFANOV (Sofia, Bulgaria)	
09:00–09:20	Oral 19	Pediatric C3 glomerulopathy: from diagnosis to clinical management	VARVARA ASKITI (Athens, Greece)	DIMITAR ROUSSINOV (Sofia, Bulgaria) SEVCAN BAKKALOGLU (Ankara, Turkey)
09:20–09:40	Oral 20	Complement in C3 glomerulopathy: Analysis of acquired and genetic drivers	NORA VESZELI (Budapest, Hungary)	
09:40–10:00	Oral 21	Does a new targeted complement therapies promise a better future for patients with C3 glomerulopathy?	DANKA POKRAJAC (Saraevo, BiH)	

10:00–10:20	Scientific symposium Supported by SOBI	Novelties in treatment of children above 12 years old with C3G and primary IC- MPGN	GALIA ZLATANOVA (Sofia, Bulgaria)	
10:20–10:30		Discussion		
10:30–11:00	Coffee Break			
Sixth session Secondary glomerulonephritis (part 1) – LN				
11:00–11:20	Oral 22	Hidden inflammation: Why renal biopsy still matters in pediatric silent lupus nephritis	ADRIAN LUNGU (Bucharest, Romania)	REZAN TOPALOGLU (Ankara, Turkey) DUSAN PARIPOVIC (Belgrade, Serbia)
11:20–11:40	Oral 23	Complete remission in Lupus nephritis – is it important?	KJELL TULLUS (London, UK)	
11:40–12:00	Oral 24	Pediatric Lupus nephritis: emerging treatment strategies and future directions	PATRICIA COSTA-REIS (Lisbon, Portugal)	
12:00–12:20	Oral 25	Rapidly progressive Lupus nephritis: therapeutic dilemmas, guideline-based management, and outcome	BRANKICA SPASOJEVIĆ (Belgrade, Serbia)	
12:20–12:40	Oral 26	Corticosteroid minimisation and treat to target in paediatric systemic Lupus erythematosus	STEPHEN MARKS (London, UK)	
12:40–12:50		Discussion		
12:50–14:00	Lunch Break			
Seventh session Secondary glomerulonephritis (part 2) – ANCA GN				
14:00–14:20	Oral 27	Clinical presentation of ANCA associated vasculitis	REZAN TOPALOGLU (Ankara, Turkey)	CONSTANTINOS STEFANIDIS (Athens, Greece) BRANKICA SPASOJEVIĆ (Belgrade, Serbia)
14:20–14:40	Oral 28	Management of ANCA associated vasculitides	SEVCAN BAKKALOGLU (Ankara, Turkey)	
14:40–15:10	Oral 29	International cooperation and European networks	MAREK MIGDAL (Warszawa, Poland)	
15:10–15:20		Discussion		

15:20–15:30	Closing remarks	
15:30–16:00	Coffee Break	
Round table		
16:00–17:00		C3 and IS-MPGN in SE part of Europe – testing, genetics, access to treatment
17:00–17:30		Discussion